A mother's stage 3 rectal cancer disappeared within five months after she received an experimental immunotherapy treatment, and her remarkable journey is now drawing renewed attention following a major medical milestone. The U.S. Food and Drug Administration (FDA) approved the drug Jemperli on October 19 for certain adults with locally advanced rectal cancer, opening a new treatment option for eligible patients.
Kelly Spill was just 28 when she learned she had stage 3 rectal cancer. At the time, she had an eight-month-old baby and was preparing for a future with her fiancé, John Bonito. The diagnosis threatened not only her health but also her hopes of having more children. Conventional treatment could involve chemotherapy, radiation and surgery, which may have lasting effects on fertility and quality of life.
After testing revealed that her tumor had a specific genetic characteristic, known as mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), Spill became eligible for a clinical trial at Memorial Sloan Kettering Cancer Center. She received Jemperli, also known as dostarlimab, an immunotherapy drug designed to help the immune system recognize and attack cancer cells.
The results changed her life. Her tumor shrank significantly during treatment and disappeared within five months. Spill was subsequently reported to have no detectable evidence of disease. She avoided the chemotherapy, radiation and surgery that had initially been considered, and later welcomed two more children. She has now remained cancer-free for more than five years.
The FDA's new approval applies specifically to adults with previously untreated stage II or stage III locally advanced rectal cancer whose tumors test positive for MSI-H or dMMR. These genetic markers are important because the treatment is not suitable for every type of rectal cancer. According to the FDA, approximately 3% of locally advanced rectal cancers have these characteristics.
The approval was based on clinical trial evidence involving eligible patients treated with Jemperli alone. The FDA reported that almost three-quarters of participants in the AZUR-1 study had not needed surgery, radiation or chemotherapy at the time of the analysis. Further follow-up is still necessary to establish how durable the responses will be. The drug can also cause serious immune-related side effects, so treatment decisions must be made with an oncology team.
For Spill, the treatment offered a future she once feared might not be possible. Her experience highlights the potential of personalized cancer care and the importance of testing tumors for specific biomarkers. While this approval will not help every rectal cancer patient, it represents an important new option for people whose tumors meet the eligibility criteria.